Stocks Crossing 50-Day SMA 10/25: (SYMC) (GTI) (ORLY) Above; (CLF) (NYT) (AMRN) Below
- Top 10 News for 2/23 - 2/27: Revised GDP Slips, but Beats, in Q4; Two Pharma Giants to Merge; Net Neutrality Passes
- UPDATE: Revised Q4 GDP Growth Slows to 2.2% as Private Inventory Investment Estimate Trimmed
- Former AIG (AIG) CEO Benmosche Dies at Age 70
- UPDATE: FDIC Takes Over Doral Bank (DRL) in Puerto Rico
- Ericsson (ERIC) Files Complaints Against Apple (AAPL) Over Patent Infringement
Crossing and above:
- Symantec Corp (Nasdaq: SYMC) - up 6.6 percent. Posts Q2 EPS of 45 cents, topping analyst expectations.
- GrafTech International Ltd. (NYSE: GTI) - up 14.3 percent. Topped Q3 earnings expectations by 4 cents per share while revs of $321 million were also strong.
- O'Reilly Automotive, Inc. (Nasdaq: ORLY) - up 3.5 percent. Ripping higher on a 5 cents earnings beat. Shares also pushed above the 100-day SMA today as well.
- Goldcorp, Inc. (NYSE: GG) - up 6.6 percent. Topped EPS expectations by 8 cents while revs of $1.5 billion were also strong.
- Cliffs Natural Resources (NYSE: CLF) - down 10.4 percent. Missed Q3 EPS views by a staggering 48 cents. Revs were also about $2.2 billion shy of expectations.
- New York Times Co. (NYSE: NYT) - down 22.4 percent. Really getting hit following the earnings miss this morning. Shares down over 22 percent after running over 55 percent higher since July.
- Amarin Corporation plc (Nasdaq: AMRN) - down 1.3 percent. Lower as Marwood Group said it doesn't see Vascepa getting NCE designation from the FDA.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allscripts (MDRX) Sees Heavy Put Activity Following Q4 Report
- Amarin (AMRN), Eddingpharm Enter Vascepa Development, Commercialization Agreement for China
- UPDATE: Libbey (LBY) Tops Q4 EPS Views
Create E-mail Alert Related CategoriesSpecial Reports, Technicals, Trader Talk
Related EntitiesEarnings, Stocks crossing the 50-day simple moving average
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!